Biofrontera AG (XTRA:B8F) has an ERP5 rank of 16239. The ERP5 Rank is an investment tool that analysts use to discover undervalued companies. The ERP5 looks at the Price to Book ratio, Earnings Yield, ROIC and 5 year average ROIC. The lower the ERP5 rank, the more undervalued a company is thought to be.

Stock analysis may be used to determine which shares the investor should buy, and at what price they should buy. Many investors will search for stocks that are currently undervalued. Fundamental research may involve scouring the balance sheet to spot a solid company. Many investors will use financial ratios to help determine which shares to purchase. Some of the more popular ratios are return on equity, earnings per share, price to earnings, and dividend yield. Applying the same type of research across the board may help the investor spot stocks that present a good opportunity for future growth.

The Q.i. Value of Biofrontera AG (XTRA:B8F) is 72.00000. The Q.i. Value is another helpful tool in determining if a company is undervalued or not. The Q.i. Value is calculated using the following ratios: EBITDA Yield, Earnings Yield, FCF Yield, and Liquidity. The lower the Q.i. value, the more undervalued the company is thought to be.

The EBITDA Yield is a great way to determine a company’s profitability. This number is calculated by dividing a company’s earnings before interest, taxes, depreciation and amortization by the company’s enterprise value. Enterprise Value is calculated by taking the market capitalization plus debt, minority interest and preferred shares, minus total cash and cash equivalents. The EBITDA Yield for Biofrontera AG (XTRA:B8F) is -0.049929.

The Earnings to Price yield of Biofrontera AG (XTRA:B8F) is -0.056463. This is calculated by taking the earnings per share and dividing it by the last closing share price. This is one of the most popular methods investors use to evaluate a company’s financial performance. Earnings Yield is calculated by taking the operating income or earnings before interest and taxes (EBIT) and dividing it by the Enterprise Value of the company. The Earnings Yield for Biofrontera AG (XTRA:B8F) is -0.052737. Earnings Yield helps investors measure the return on investment for a given company. Similarly, the Earnings Yield Five Year Average is the five year average operating income or EBIT divided by the current enterprise value. The Earnings Yield Five Year average for Biofrontera AG is -0.027483.

The FCF Yield 5yr Average is calculated by taking the five year average free cash flow of a company, and dividing it by the current enterprise value. Enterprise Value is calculated by taking the market capitalization plus debt, minority interest and preferred shares, minus total cash and cash equivalents. The average FCF of a company is determined by looking at the cash generated by operations of the company. The Free Cash Flow Yield 5 Year Average of Biofrontera AG (XTRA:B8F) is -0.028221.

**Price Index**

We can now take a quick look at some historical stock price index data. Biofrontera AG (XTRA:B8F) presently has a 10 month price index of 1.47837. The price index is calculated by dividing the current share price by the share price ten months ago. A ratio over one indicates an increase in share price over the period. A ratio lower than one shows that the price has decreased over that time period. Looking at some alternate time periods, the 12 month price index is 1.67507, the 24 month is 1.98737, and the 36 month is 2.68282. Narrowing in a bit closer, the 5 month price index is 1.03640, the 3 month is 1.15444, and the 1 month is currently 0.94322.

**Returns**

Looking at some ROIC (Return on Invested Capital) numbers, Biofrontera AG (XTRA:B8F)’s ROIC is -3.000671. The ROIC 5 year average is -2.436920 and the ROIC Quality ratio is -0.227622. ROIC is a profitability ratio that measures the return that an investment generates for those providing capital. ROIC helps show how efficient a firm is at turning capital into profits.

Biofrontera AG (XTRA:B8F) has a Price to Book ratio of 15.395805. This ratio is calculated by dividing the current share price by the book value per share. Investors may use Price to Book to display how the market portrays the value of a stock. Checking in on some other ratios, the company has a Price to Cash Flow ratio of -22.463136, and a current Price to Earnings ratio of -17.710802. The P/E ratio is one of the most common ratios used for figuring out whether a company is overvalued or undervalued.

Biofrontera AG (XTRA:B8F) presently has a current ratio of 8.87. The current ratio, also known as the working capital ratio, is a liquidity ratio that displays the proportion of current assets of a business relative to the current liabilities. The ratio is simply calculated by dividing current liabilities by current assets. The ratio may be used to provide an idea of the ability of a certain company to pay back its liabilities with assets. Typically, the higher the current ratio the better, as the company may be more capable of paying back its obligations.

The Price to book ratio is the current share price of a company divided by the book value per share. The Price to Book ratio for Biofrontera AG XTRA:B8F is 15.395805. A lower price to book ratio indicates that the stock might be undervalued. Similarly, Price to cash flow ratio is another helpful ratio in determining a company’s value. The Price to Cash Flow for Biofrontera AG (XTRA:B8F) is -22.463136. This ratio is calculated by dividing the market value of a company by cash from operating activities. Additionally, the price to earnings ratio is another popular way for analysts and investors to determine a company’s profitability. The price to earnings ratio for Biofrontera AG (XTRA:B8F) is -17.710802. This ratio is found by taking the current share price and dividing by earnings per share.

Investing in the stock market can sometimes draw intense emotion from individual investors. When the market slips into a chaotic state, some investors may let their emotions get the best of them which can lead to impulsive decisions. On the other side of the coin, market chaos may cause certain investors to freeze in a panic. This may mean that the investor becomes shaken to the point that they are unable to make any decisions let alone an educated one. Discipline is a quality shared by many successful traders and investors. Staying committed to the plan, whether short-term or long-term, can help investors make it through those times of extreme market uncertainty.